We develop and manufacture diverse cell therapies including CD34+ hematopoietic stem cells, autologous and allogenic T-cells, and NK cells. Our cell therapy capabilities cover numerous technologies, ranging from closed to open systems at different scales, depending on client needs. We also develop and manufacture adeno-associated viral vectors, lenti viral vectors and retro viral vectors. Our ready-to-use platform capabilities are built on cell factories (up to 48L) and bioreactors (up to 200L) using adherent processes, designed entirely in-house.
Each year, over 100 world-leading experts present their latest research at ESGCT. From Nobel Prize winners to scientists at the very cutting-edge of the field; ESGCT’s Annual Congress features the hot topics and ground-breaking research in gene and cell therapy.